X4 Pharmaceuticals, Inc. (XFOR)
X4 Pharmaceuticals, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
X4 Pharmaceuticals, Inc. (XFOR) is a Biotechnology company based in US with a market capitalization of $348M. Free cash flow was negative at -$88.6M. This page tracks XFOR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 143 employees · IPO Nov 16, 2017
Valuation
Valuation & price
$3.94as of May 17, 2026· -15.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.87
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$348M
Market cap
—
Revenue growth (YoY)
82.2%
Gross margin
-$88.6M
Free cash flow (USD)
-$175.7M
Net debt
Net cash position
531.0%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2024 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
1
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 6, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider sellJul 1, 2026Filing
Insider Sell $36KKIRSKE DAVID · Chief Financial Officer · $36.4K
- 8-K eventJul 1, 2026Filing
Director Appointment
- 8-K eventMay 13, 2026Filing
Equity Incentive Plan Amended
- 8-K eventMay 12, 2026Filing
Equity Incentive Plan Update
- Quarterly reportMay 6, 2026Filing
10-Q Filed
- FinancingMay 6, 2026Filing
Securities Registration
Questions
Frequently asked questions
What is X4 Pharmaceuticals, Inc.'s market cap?
X4 Pharmaceuticals, Inc. (XFOR) has a market capitalization of $348M.
What is XFOR's P/E ratio?
A meaningful P/E ratio is not available for XFOR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is XFOR's price-to-book (P/B) ratio?
XFOR trades at 1.87 times book value per share.
Are insiders buying XFOR stock?
SEC Form 4 filings show no open-market insider buys at X4 Pharmaceuticals, Inc. in the last 90 days (1 sell).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.